131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study

131I-LNTH-1095+enzalutamide was associated with a statistically significant improvement in PSA50 response compared to enzalutamide alone despite a lower dosing schedule (4 cycles of 3.7 GBq/dose every 8 weeks) than the other approved PSMA RLT agents. Grade ≥3 adverse events were more frequent with combination therapy, particularly hematologic toxicity. NCT03939689.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-03-04
DOI
https://doi.org/10.1158/1078-0432.ccr-25-4948
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study

Gennady Bratslavsky, Iryna Teslenko, David L. Laidley, Gary A. Ulaner et al.
Clinical Cancer Research
Prostate Cancer Treatment and Research
article

131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study

Gennady Bratslavsky, Iryna Teslenko, David L. Laidley, Gary A. Ulaner, Minal Vasanawala, Yusuf Menda, Frédéric Pouliot, Yang Lu, Jérémie Calais, Jean-Claude Provost, Evan Y. Yu, Michael B. Lilly, Neil Fleshner, Giuseppe Esposito, Russell Szmulewitz, Vivek Narayan, Fred Saad, Nand Kishore. Rawat
article en

Abstract

131I-LNTH-1095+enzalutamide was associated with a statistically significant improvement in PSA50 response compared to enzalutamide alone despite a lower dosing schedule (4 cycles of 3.7 GBq/dose every 8 weeks) than the other approved PSMA RLT agents. Grade ≥3 adverse events were more frequent with combination therapy, particularly hematologic toxicity. NCT03939689.

Clinical Cancer Research
University of Southern California (US), University of Iowa (US), The University of Texas MD Anderson Cancer Center (US), Medical University of South Carolina (US), University of California, Los Angeles (US), Georgetown University (US), University of Toronto (CA), SUNY Upstate Medical University (US), VA Palo Alto Health Care System (US), London Health Sciences Centre (CA), MedStar Georgetown University Hospital (US), University of Chicago (US), Fred Hutch Cancer Center (US), Duchossois Group (United States) (US), Centre hospitalier universitaire de Québec (CA), Bedford Research Foundation (US), Centre hospitalier de l'Université Laval (CA), Centre Hospitalier de l’Université de Montréal (CA), Iowa City Public Library (US), Hoag Orthopedic Institute (US), University of Pennsylvania (US)
London Health Sciences Centre
Good health and well-being
Openalex Percentile: Top 33%
Prostate Cancer Treatment and Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.